340B Compliance Issues Requiring Repayment to Manufacturers

SPONSORED CONTENT

Resolving 340B noncompliance can be a time-consuming task for 340B participants — and one of the greatest challenges in managing a 340B program. This guide outlines the five steps to successfully navigate resolving compliance issues requiring repayment to manufacturers, from discovery to resolution, and includes a solution to help streamline the refund process.

Step #1: Discovering 340B Program Noncompliance

Program noncompliance can be detected in four ways: self-audit, HRSA audit, manufacturer good faith inquiries or audits, and through normal day-to-day operations. Compliance issues are most commonly identified through self-audits conducted either by an internal audit department, pharmacy department, or an outside contractor hired by a covered entity.

“A compliance issue such as incorrect 340B accumulation quantities may be caused by systemic failures such as a data feed transmission error. In my experience as a 340B team member, we had analysts dedicated to reviewing specific program areas to monitor our program for noncompliance on an ongoing

Read More »

340B Policies and Procedures: The Keys to Compliant Savings

Minh Hoang headshot

SPONSORED CONTENT

For 340B covered entities (CEs), a Health Resources and Services Administration (HRSA) audit is an inevitability. While you won’t be able to predict when HRSA comes calling, you can bank on sooner or later being one of the 200 CEs HRSA audits every year. That’s why Cloudmed recommends keeping your organization’s policies and procedures aligned with current 340B program guidance and expert interpretations. When the audit comes, you want to be one of the CEs with a clean outcome, not one of those saddled with findings that could jeopardize your program.  

A critical component of a compliant 340B program is having your policies and procedures in good order before the audit. They must identify how you ensure key compliance measures are met for the 340B program, including patient definition, care setting, and other factors.  

Beyond setting the applicable policies and procedures, you must ensure you

Read More »

Expert Tip From Ravin Consultants

img
img

TIP: When using outsourced telehealth services, be prepared to “Mind the Gap.”


Telehealth services are a great

Read More »

340B Financial Health Check

Mike Phillips headshot

SPONSORED CONTENT

Leaders of hospitals, health centers and other 340B provider institutions are busy and don’t have time in their demanding days to be involved in the detailed, day-to-day financial oversight of their 340B programs. Yet, they also can’t afford to leave valuable program dollars on the table, which fund vital and expanded patient services. Here’s a checklist of six key steps to help you optimize the financial health of your 340B program in 2023 and beyond. And if you have a 340B TPA (third-party administrator), this list can help you ask them the right questions.

340B Financial Checklist

1. Know the facts about your contracts and fees
  • Be sure you know how you’re charged by your 340B TPA. Is it a flat fee per contract pharmacy, a flat fee and percentage of savings on 340B approved claims, or other?
  • Are there minimum dollar amount thresholds you must meet? 
Read More »

Key Takeaways From the 340B Winter Coalition Conference

SPONSORED CONTENT

With new contract pharmacy restrictions recently announced, and more expected to come in the near future, ensuring compliance is more important than ever in the world of 340B. Here are a few takeaways from last week’s 340B Coalition winter conference in San Diego to help you and your 340B program prepare for the changes ahead.

More Restrictions

Drug manufacturers are getting increasingly restrictive regarding 340B pricing for contract pharmacy relationships. In just the past few days, Pfizer, GSK and Novartis have announced new restrictions, with GSK’s restrictions applying to all covered entities.  Most of these companies are now only going to allow the use of 340B discounts in the contract pharmacy setting at the covered entity’s in-house retail pharmacy.  The only exception is if the covered entity does not have an in-house outpatient pharmacy, they may designate one contract pharmacy location.  In some of these instances, covered entities must also:

Read More »

Expert Tip From PharmaForce

img
img

TIP: When approving your 340B wholesaler invoices for payment, make sure to compare the invoiced amount to your 340B catalog or the ceiling

Read More »

Expert Tip From Visante

img
img

TIP: For any covered entities with a contract pharmacy program, it is critical to review carve-out/ineligible claims data from your TPA system(s) to

Read More »

The Top 5 Marketing Tips for Building Your Patient Base

digital hands of doctor holding heart symbol

SPONSORED CONTENT

Saving people’s lives.
Eliminating the stigma surrounding a host of physical and mental health conditions.
Advocating for the health equity of underserved populations.
Executing targeted marketing campaigns.

One of these initiatives indeed feels less service-oriented than the others. But once you kick all its associated buzzwords to the curb, marketing is crucial to a covered entity’s ability to fulfill its vision.

Whether it’s because they’re too busy fighting fires, feel like they don’t have the financial resources, or believe they lack the expertise to get the word out about their services successfully, covered entities often shy away from strategic marketing plans. Unfortunately, doing so can keep them from attracting and retaining patients and, as a result, threaten the sustainability of their missions.

Read on as Avita Care Solution’s Chief Marketing Officer Liz Eckert and Chief Advocacy Officer Glen Pietrandoni explain why covered entities must thoughtfully promote themselves to patients in an

Read More »

AHF: Addressing Syphilis Disparities in Franklin County, OH

Aids Healthcare Foundation logo

SPONSORED CONTENT

In 1999, the Centers for Disease Control and Prevention (CDC) launched the National Campaign to Eliminate Syphilis from the United States. The CDC updated its ambitious plan in 2006 and aimed to reduce rates of primary and secondary syphilis to less than 2.2 cases per 100,000 population, congenital syphilis to less than 3.9 cases per 100,000, and the racial disparity between rates of syphilis among Black and White individuals to less than 3:1. Despite having moderate success at the turn of the century, the US is experiencing a drastic resurgence of syphilis. In 2021, the CDC reported 171,074 total cases of syphilis nationally, a 68.4% increase from 2017. Worse, there has been a sharp increase in the number of babies born with syphilis; cases of congenital syphilis rose 184.5% to 2,677 cases between 2017 and 2021.

Like other sexually transmitted infections (STIs), syphilis disparities remain with regards to

Read More »

Expert Tip From CPS

img
img

TIP: For sites submitting data to 340B ESP, the option exists within the 340B ESP portal to “Attest” for several manufacturers which will

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report